STMC-103H is under clinical development by Siolta Therapeutics and currently in Phase II for Allergic Asthma. According to GlobalData, Phase II drugs for Allergic Asthma have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STMC-103H’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STMC-103H overview

STMC-103H is under development for the treatment and prevention of atopic immunoglobulin E-mediated allergic disorder, allergic asthma, food allergy, atopic dermatitis, allergic rhinitis and other allergic diseases. It is a live bacteria containing consortia of intestinal bacteria and is administered through oral route.

Siolta Therapeutics overview

Siolta Therapeutics, is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company is headquartered in United States.

For a complete picture of STMC-103H’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.